The "Veeva 2015 Paperless TMF Survey: Annual CRO Report" reveals a significant increase in the number of contract research organizations (CROs) using electronic trial master file (eTMF) applications from just one year ago. The global study of TMF owners found that 38% of CROs surveyed now use eTMF applications versus just 21% in 2014. A number of benefits are prompting CROs’ adoption of eTMF technology. More than half (58%) say faster study start-up is a key driver, while 50% cite cost savings.
The industry-wide study also shows a notable shift away from paper and paper-based processes. CRO respondents are adopting electronic processes across content-intensive areas, including clinical operations, regulatory, drug safety, and data management. The data management area saw the largest decrease in its use of paper, down from 27% in 2014 to 8% in 2015. Clinical operations, which manages the greatest number of TMF documents overall, also saw a sharp decline from 47% in 2014 to 34% in 2015.
Read the full release.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.